Professor  is a Professor and the Director of the Department of Gastric Surgery at the Sun Yat-sen University Cancer Center (SYSUCC). Professor Zhou obtained his Bachelor in Medicine in 1984 and Ph.D. in 2007 at the Sun Yat-sen University of Medical Sciences, P. R. China. He started his residency training at the China-Japan Friendship Hospital in Beijing in 1984, which he continued at the Sun Yat-sen University Cancer Center in the Department of Abdominal Surgery from 1986 to 1991. He was promoted to Attending Surgeon, Associate Professor, and Professor in 1991, 1998, and 2004, respectively.

He has extensive experience and expertise in the diagnosis and treatment of abdominal malignancies (including gastric cancer, retroperitoneal tumors, neuroendocrine tumors, and gastrointestinal tumors) and melanoma for over 30 years. He also specializes in the surgical treatment of gastric cancer.

Professor Zhou was appointed as the Director of the Department of Gastric Surgery in SYSUCC in 2009 and still holds this position. He also has many academic posts such as the President of Gastric Cancer Specialty Committee of the Guangdong Provincial Anti-cancer Association (2013-2017), the vice-president of theGastric Cancer Expert Committee of theChinese Society of Clinical Oncology (2017-2021), and more.

His current focus is to improve the early diagnosis and multidisciplinary treatments of gastric cancer. He masters the open, laparoscopic, and robotic surgeries for gastric cancer. Regarding research work, he focuses on the neoadjuvant chemotherapy,immunotherapy, chemoradiation, and molecular typing of gastric cancer. Professor Zhou has published 3 editorial books and more than200 research papers.

(1) Neoadjuvant chemotherapy for advanced gastric cancer: Conduct both basic and clinical research (including prospective randomized controlled clinical trials) on neoadjuvant chemotherapy for advanced gastric cancer,propose effective regimens of neoadjuvant chemotherapy and immunotherapy for advanced gastric cancer.

(2) Chemoradiation for locally advanced gastric cancer: Conduct both basic and clinical research on the chemoradiation for locally advanced gastric cancer.

 (3) Translational research on molecular typing of gastric cancer: Explore the molecular types of gastric cancer using gene chips, tissue microarray, RNA sequencing technology, and more, to identify more accurate methods for predicting the prognosis and evaluate the treatment response, including sensitivity to chemotherapy and/or radiotherapy, of gastric cancer patients.

 

Doctor of Philosophy (Ph.D.) in Surgical Oncology from the Sun Yat-sen University (Guangzhou, P. R. China), 2007.

Post Graduate Training in General Surgery, Royal Adelaide Hospital (Adelaide, Australia), 2003.

Master in Medicine from the Sun Yat-sen University of Medical Sciences (Guangzhou, P. R. China), 1999.

Bachelor of Medicine from the Sun Yat-sen University of Medical Sciences (Guangzhou, P. R. China), 1984.

1. Wang W, Yang YJ, Zhang RH, Deng JY, Sun Z, Seeruttun SR, Wang ZN, Xu HM, Liang H,Zhou ZW. Standardizing the classification of gastric cancer patients with limited and adequate number of retrieved lymph nodes: an externally validated approach using real-world data.Mil Med Res.2022 Apr 7;9(1):15.

2. Chen XJ, Chen GM, Wei YC, Yu H, Wang XC, Zhao ZK, Luo TQ, Nie RC,Zhou ZW. Palliative Gastrectomy versus Gastrojejunostomy for advanced Gastric cancer with outlet obstruction: a propensity score matching analysis. BMC Cancer. 2021 Feb 23;21(1):188.

3. Wu T, Wang CH, Wang W, Liu LL, Yun JP,Zhou ZW. Association of preoperative and postoperative CA72-4 with gastric cancer outcome.J Surg Oncol.2021;123(8):1699-1707.

4. Wang W, Peng Y, Feng X, Zhao Y, Seeruttun SR, Zhang J, Cheng Z, Li Y, Liu Z,Zhou Z. Development and Validation of a Computed Tomography-Based Radiomics Signature to Predict Response to Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer.JAMA Netw Open.2021;4(8):e2121143.

5. Seeruttun SR, Xu L, Wang F, Yi X, Fang C, Liu Z, Wang W,Zhou Z. A homogenized approach to classify advanced gastric cancer patients with limited and adequate number of pathologically examined lymph nodes.Cancer Commun (Lond). 2019;39(1):32.

6. Nie RC, Chen FP, Yuan SQ, Luo YS, Chen S, Chen YM, Chen XJ, Chen YB, Li YF,Zhou ZW. Evaluation of objective response, disease control and progression-free survival as surrogate end-points for overall survival in anti-programmed death-1 and anti-programmed death ligand 1 trials.Eur J Cancer. 2019;106:1-11.

7. Liu X, Wu Z, Lin E, Li W, Chen Y, Sun X,Zhou Z. Systemic prognostic score and nomogram based on inflammatory, nutritional and tumor markers predict cancer-specific survival in stage II-III gastric cancer patients with adjuvant chemotherapy.Clin Nutr. 2019;38(4):1853

8. Liang Y, Hou T, Que Y, Zhao B, Xiao W, Zhang X,Zhou Z. Elevated Controlling Nutritional Status (CONUT) Score is Associated with Poor Long-term Survival in Patients with Low-grade Soft-tissue Sarcomas Treated with Surgical Resection.Clin Orthop Relat Res. Published online April 27, 2019.

9. Wang W, Sun Z, Deng JY, Qi XL, Feng XY, Fang C, Ma XH, Wang ZN, Liang H, Xu HM,Zhou ZW. A novel nomogram individually predicting disease-specific survival after D2 gastrectomy for advanced gastric cancer.Cancer Commun (Lond). 2018;38(1):23.

10. Fang C, Wang W, Feng X, Sun J, Zhang Y, Zeng Y, Wang J, Chen H, Cai M, Lin J, Chen M, Chen Y, Li Y, Li S, Chen J,Zhou Z. Nomogram individually predicts the overall survival of patients with gastroenteropancreatic neuroendocrine neoplasms.Br J Cancer. 2017;117(10):1544-1550.